logo

For the Inventor, By the Inventor

Taichung, Taiwan

Der-Yang Cho

This inventor holds 17 USPTO granted patents and 21 published patent applications and 5 EPO patents. Top assignees: China Medical University Hospital, China Medical University, Ever Supreme Bio Technology Co. Ltd. Active years: 2018-2026.

USPTO Granted Patents = 17 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.1

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:

goldMedal11 out of 20 
 
China Medical University Hospital
 patents
silverMedal6 out of 110 
 
China Medical University
 patents
bronzeMedal1 out of 1 
 
Ever Supreme Bio Technology Co. Ltd
 patent
4. 1 out of 1 
 
Shine-On Biomedical Co., Ltd.
 patent
5. 1 out of 1 
 
Shine-On Biomedical Co., Ltd.
 patent
where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...
Loading Chart...
17 patents (USPTO):Explore Patents
1. 12594344 - PRODUCTION OF EXOSOMES AND USES THEREOF (2026-04-07),
2. 12509519 - MULTISPECIFIC SINGLE DOMAIN ANTIBODIES CHIMERIC ANTIGEN RECEPTOR AND T-CELL ENGAGER, NUCLEIC ACID, EXPRESSING CELL THEREOF, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, AND METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELL (2025-12-30),
3. 12319729 - Anti-specific antibody and nucleic acid encoding sequence thereof, and uses of the same (2025-06-03),
4. 12277926 - Intelligent medical speech automatic recognition method and system thereof (2025-04-14),
5. 12221483 - Fusion protein and nucleic acid encoding sequence thereof, and uses of the same (2025-02-11),
6. 12012454 - Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same (2024-06-18),
7. 11969727 - Tumor microenvironment on chip (2024-04-30),
8. D1007520 - Display screen or portion thereof with graphical user interface (2023-12-12),
9. 11795227 - Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same (2023-10-24),
10. 11795224 - Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same (2023-10-24),
11. 11685784 - Anti-immune-checkpoint nanobody and nucleic acid encoding sequence thereof, and uses of the same (2023-06-27),
12. 11554140 - Nucleic acid, chimeric antigen receptor expression plasmid, chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer (2023-01-17),
13. 11479611 - HLA-G specific chimeric antigen receptor, nucleic acid, HLA-G specific chimeric antigen receptor expression plasmid, HLA-G specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer (2022-10-25),
14. 11352655 - Method of identification of methicillin-resistant (2022-06-07),
15. 10988733 - Methods for obtaining pluripotent adult olfactory stem cells from an olfactory mucosa tissue (2021-04-27),

Title: The Innovative Journey of Der-Yang Cho: Pioneering Immunomodulation in Taichung

Introduction: Der-Yang Cho, a prolific inventor based in Taichung, Taiwan, has left an indelible mark in the field of immunomodulation and anti-tumor research. With a total of 10 patents under his belt, Cho's groundbreaking work continues to revolutionize the medical landscape.

Latest Patents: Among his latest patents is the "Display screen or portion thereof with graphical user interface" and the groundbreaking "Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same." This patent focuses on a nanobody that specifically binds to human leukocyte antigen-G, programmed cell death ligand 1, and CD3 ε for treating cancer and immune-related disorders.

Career Highlights: Der-Yang Cho has made significant contributions during his tenure at institutions such as China Medical University Hospital and China Medical University. His innovative research and patented inventions have propelled advancements in the field of immunomodulation, earning him recognition as a key figure in the industry.

Collaborations: Throughout his career, Cho has collaborated with esteemed colleagues such as Shao-Chih Chiu and Chih-Ming Pan. Together, they have worked tirelessly to drive innovation, foster new ideas, and bring revolutionary concepts to life in the realm of medical research.

Conclusion: Der-Yang Cho's dedication to pioneering advancements in immunomodulation and anti-tumor therapies showcases his unwavering commitment to improving healthcare outcomes. His profound impact on the field serves as a testament to his ingenuity and unwavering pursuit of excellence in the realm of medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…